Skip to main content
Journal of Patient-Reported Outcomes

Table 4 Multivariate analysis for comparison of outcomes according to patients’ self-management of AEs

From: Patients’ self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study

Outcomes

Patients’ self-management of AEs

Next follow-up (N = 71)

6 months (N = 47)

12 months (N = 30)

Coeff.

SE

p value

Coeff.

SE

p value

Coeff.

SE

p value

FKSI-15

Well (ref. poor)

4.16

1.46

0.006a

0.31

2.24

0.891b

1.88

3.69

0.619c

EQ-5D-5L

Well (ref. poor)

0.03

0.02

0.108d

-0.02

0.03

0.444e

 < −0.01

0.03

0.883f

EQVAS

Well (ref. poor)

8.79

3.26

0.009 g

-9.19

5.19

0.087 h

7.32

4.60

0.138i

Treatment duration

Well (ref. poor)

NA

NA

NA

NA

NA

NA

18.06

168.80

0.915j

  1. The p values of ‘a to i’ were estimated using sequential conditional mean models, adjusted with the following variables other than the fixed confounding variables, presenting R squares which mean each explanatory power of the models: aFKSI-15 and ECOG PS at baseline, R2 = 78%; bFKSI-15 at next follow-up, treatment duration, disease duration, ECOG PS at baseline and 6 months, and metastasis site at 6 months (bone), R2 = 65%; cFKSI-15 at 6 months, disease duration, ECOG PS at 6 months and 12 months, and intervention schedule change at 12 months, R2 = 76%; dEQ-5D-5L at baseline, BMI, histology, ECOG PS at baseline, and metastasis site at baseline (bone, brain, and pancreas), R2 = 72%; eEQ-5D-5L at next follow-up and metastasis site at 6 months (lung, bone), R2 = 60%; fEQ-5D-5L at 6 months, metastasis site at 6 months (LN), and ECOG PS at 12 months, R2 = 85%; gEQVAS at baseline, BMI, and metastasis site at baseline (bone, LN, brain), R2 = 65%; hEQVAS at next follow-up, BMI, disease duration, operation, and metastasis site at baseline (lung) and at 6 months (bone), R2 = 65%; and iEQVAS at 6 months, disease duration, metastasis site at 12 months (LN, bone), and response criteria at 12 months, R2 = 72%
  2. The p value of j was estimated using a linear regression model adjusted with the following variables other than the fixed confounding variables: response criteria at 6 months and metastasis site at 6 months (brain)
  3. BMI, body mass index; coeff., coefficient; EQ-5D-5L, EuroQol-Five Dimensional-Five Level; EQVAS, EuroQol-visual analog scale; ECOG PS, Eastern Cooperative Oncology Group performance status; FKSI-15, Functional Kidney Symptom Index-15; LN, lymph node; NA, not applicable
Back to article page